BioAge Labs ^{Priced, Nasdaq: BIOA}

We are building a pipeline of platform-derived therapeutics targeting chronic metabolic disease. Our lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) where activation has the potential to recapitulate many of the benefits of exercise. We are developing azelaprag for the treatment of obesity in combination with GLP-1R agonists with the goal of increasing overall weight loss, with the potential to also improve tolerability and body composition. We have initiated one Phase 2 clinical trial of azelaprag in combination with tirzepatide and plan to initiate a second Phase 2 clinical trial of azelaprag in combination with semaglutide in the first half of 2025. We are also developing a series of oral small molecule inhibitors of NLRP3, a key driver of neuroinflammation, which is linked to many diseases including obesity. We anticipate submitting an IND for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. From our platform, we have several additional targets with product candidates in discovery stages, and we are also continuously seeking to identify and develop further promising targets.